Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: MCV4 vaccine - Novartis; MenACWY-CRM; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline; Novartis; Tianjin CanSino Biotechnology
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 12 Sep 2017 The Therapeutics Goods Administration approves Meningococcal vaccine groups A C Y W- 135 conjugate for treatment of Meningococcal infections (In Infants aged less than 12-months, Prevention) in Australia
  • 06 Dec 2016 GlaxoSmithKline plans a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA (IM) (NCT02986854)
  • 01 Dec 2016 GlaxoSmithKline initiates a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA (IM) (NCT02986854)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top